Evogene Ltd. (EVGN): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage rapide de la biotechnologie agricole, Evogene Ltd. (EVGN) apparaît comme une force pionnière, tirant parti de la biologie informatique et de l'apprentissage automatique de pointe pour révolutionner l'amélioration des cultures. En transformant la recherche génétique en solutions puissantes et durables, l'entreprise est à l'avant-garde de l'innovation agricole, offrant un potentiel sans précédent pour améliorer les performances des cultures, réduire les délais de développement et relever les défis mondiaux de la sécurité alimentaire grâce à ses technologies de reproduction prédictives sophistiquées.

Evogene Ltd. (EVGN) - Modèle d'entreprise: partenariats clés

Institutions de recherche de la biotechnologie agricole

Evogene Ltd. a établi des partenariats stratégiques avec les institutions de recherche suivantes:

Institution	Focus de partenariat	Année établie
Université hébraïque de Jérusalem	Collaboration de recherche génomique	2018
Volcani Agricultural Research Center	Technologies d'amélioration des cultures	2019

Sociétés de production de semences et de cultures

Les principaux partenariats dans la production de semences et de cultures comprennent:

• Corteva Agriscience
• Science des cultures de Bayer
• Syngenta AG

Entreprises chimiques et technologies agricoles

Partenariats collaboratifs avec les entreprises technologiques:

Entreprise	Collaboration technologique	Valeur du contrat
Science des cultures de Bayer	Développement de traits microbiens	3,2 millions de dollars
Corteva Agriscience	Optimisation de trait génétique	2,7 millions de dollars

Centres de recherche universitaires

Collaborations de recherche en génomique:

• Institut des sciences de Weizmann
• Université de Tel Aviv
• Université Ben Gourion du Néguev

Capital-risque et sociétés d'investissement

Partenariats d'investissement soutenant les innovations Agritech:

Entreprise de capital-risque	Montant d'investissement	Année d'investissement
Terra Mg Ventures	5,1 millions de dollars	2022
Pontifax Agtech	4,8 millions de dollars	2021

Evogene Ltd. (EVGN) - Modèle d'entreprise: Activités clés

Biologie informatique et développement de traits génétiques

Evogene a investi 6,2 millions de dollars dans la R&D de biologie informatique au cours de l'exercice 2023. La société maintient 12 plateformes de développement de traits de calcul propriétaires.

Type de plate-forme	Nombre de plateformes actives	Investissement annuel
Génétique des cultures	5	2,7 millions de dollars
Traits microbiens	3	1,5 million de dollars
Génomique avancée	4	2 millions de dollars

Apprentissage automatique et plates-formes d'amélioration des cultures basées sur l'IA

Evogène emploie 22 spécialistes de l'apprentissage de l'IA et de la machine. L'entreprise a développé 7 algorithmes de renforcement des cultures basées sur l'IA propriétaire.

• Coût total de développement de la plate-forme d'IA: 4,3 millions de dollars en 2023
• Brevets d'apprentissage automatique: 16 inscrits
• Attribution annuelle des ressources informatiques: 3 500 heures de calcul

Découverte et optimisation des traits génomiques

Le budget de la recherche génomique en 2023 était de 5,8 millions de dollars. La société a identifié et optimisé 43 nouveaux traits génétiques à travers les segments agricoles.

Catégorie de recherche	Traits découverts	Taux d'optimisation
Résilience des cultures	18	72%
Renforcement du rendement	15	65%
Tolérance au stress	10	58%

Licence et commercialisation des technologies agricoles

Evogène a généré 3,2 millions de dollars parmi les licences technologiques en 2023. Accords de licence actifs: 9 avec les grandes sociétés agricoles.

Recherche et développement de nouvelles solutions d'amélioration des cultures

Les dépenses de R&D ont totalisé 14,6 millions de dollars en 2023. La société conserve 28 programmes de recherche actifs dans les domaines de la biotechnologie agricole.

• Personnel de recherche total: 87 scientifiques
• Installations de recherche avancées: 4 laboratoires dédiés
• Demandes de brevets annuelles: 12

Evogene Ltd. (EVGN) - Modèle d'entreprise: Ressources clés

Technologies de reproduction prédictive de calcul propriétaire

Evogene Ltd. a développé plateformes de reproduction prédictive informatique dans plusieurs domaines agricoles:

Plate-forme technologique	Focus spécifique	Étape de développement
Trait agricole	Amélioration des traits de culture	Opérationnel
Graines AG	Optimisation génétique des graines	Opérationnel
Ag-biologiques	Développement de traits microbiens	Développement avancé

Bases de données génomiques avancées et bibliothèques de traits génétiques

Les ressources génomiques comprennent:

• Base de données de traits génétiques propriétaires avec plus de 250 000 marqueurs génétiques
• Modèles de prédiction des traits génétiques compatibles avec l'apprentissage automatique
• Repositaires de séquence génomique multi-espèces

Équipes de recherche scientifique et informatique spécialisées

Catégorie d'équipe	Nombre de chercheurs	Domaines d'expertise
Biologie informatique	37	Bioinformatique, apprentissage automatique
Génie génétique	28	CRISPR, modification génomique
Science des données	22	Modélisation statistique, AI

Portefeuille de propriété intellectuelle

Composition de la propriété intellectuelle:

• Brevets totaux: 64
• Familles de brevets: 18
• Demandes de brevet en instance: 22

Algorithmes de bioinformatique et d'apprentissage automatique

Type d'algorithme	Capacité de calcul	Domaine d'application
Algorithme de prédiction des traits	Taux de précision de 98,3%	Potentiel génétique des cultures
Modèle de sélection génomique	2,7x plus vite que les méthodes traditionnelles	Efficacité d'élevage
Classificateur d'apprentissage automatique	95,6% de performance prédictive	Analyse de la variation génétique

Evogene Ltd. (EVGN) - Modèle d'entreprise: propositions de valeur

Développement avancé des traits génétiques pour la productivité agricole

Evogene Ltd. développe des traits génétiques ciblant plusieurs types de cultures avec des caractéristiques de performance spécifiques.

Type de culture	Focus de traits génétiques	Cible de performance
Maïs	Résistance à la sécheresse	Amélioration des rendements de 15 à 20%
Soja	Résistance aux ravageurs	12-18% ont réduit les dégâts des cultures
Canola	Contenu à l'huile améliorée	10-15% ont augmenté le rendement en pétrole

Solutions d'amélioration des cultures rentables

Les plateformes de reproduction de calcul d'Evogene réduisent les coûts de recherche et de développement.

• Réduction des coûts de R&D: 30 à 40% par rapport aux méthodes de reproduction traditionnelles
• Temps de cycle de développement: 4-5 ans contre 7 à 10 ans
• Précision de prédiction informatique: 85 à 90% de performance de trait

Performance et potentiel de rendement accrus

L'optimisation génétique des traits se concentre sur les principales mesures de performance agricole.

Métrique de performance	Plage d'amélioration
Augmentation du rendement	10-25%
Efficacité de l'eau	15-30%
Résistance aux ravageurs	20-40%

Innovations technologiques agricoles durables

Evogène développe des solutions génétiques soucieuses de l'environnement.

• Réduction de l'utilisation des pesticides chimiques: 25-50%
• Potentiel de conservation de l'eau: jusqu'à 40% de réduction
• Réduction de l'empreinte carbone: 15-30% par cycle de culture

Plates-formes de reproduction de précision réduisant le temps de développement et les coûts

La génomique informatique accélère le processus de développement des traits.

Capacité de plate-forme	Métrique de performance
Prédiction génomique	Précision à 90%
Vitesse de découverte de traits	50% plus rapide que les méthodes traditionnelles
Création de renforcement	Réduction des coûts de 35 à 45%

Evogene Ltd. (EVGN) - Modèle d'entreprise: relations avec les clients

Accords de licence de technologie

En 2024, Evogene Ltd. maintient des accords de licence de technologie avec des sociétés agricoles et biotechnologiques. La stratégie de licence de l'entreprise se concentre sur l'accès à ses technologies génétiques propriétaires.

Type de licence	Nombre d'accords actifs	Revenus annuels estimés
Génomique agricole	7 accords	2,3 millions de dollars
Génétique microbienne	3 accords	1,5 million de dollars

Partenariats de recherche collaborative stratégique

Evogene s'engage dans des collaborations de recherche stratégique avec des partenaires clés de l'industrie.

• Partenariats totaux de recherche active: 5
• Durée du partenariat: 2-4 ans
• Investissement total de recherche collaborative: 4,7 millions de dollars

Services de support technique et de consultation

La société fournit un support technique spécialisé sur ses plateformes technologiques.

Catégorie de support	Niveau de service	Revenus de services annuels
Conseil génomique	Équipes de soutien dédiées	1,2 million de dollars
Aide à la mise en œuvre	Conseils techniques personnalisés	$900,000

Transfert de technologie basé sur les performances

Evogene implémente les mécanismes de transfert de technologie liés aux performances avec les clients.

• Paiements basés sur les jalons: Lié à des réalisations spécifiques au développement technologique
• Métriques de performance suivies: amélioration des traits génétiques, amélioration du rendement
• Accords de transfert totaux basés sur les performances: 4

Engagement scientifique et commercial en cours

La société maintient un engagement continu avec les parties prenantes scientifiques et commerciales.

Type d'engagement	Fréquence	Volume d'interaction annuel
Conférences scientifiques	Trimestriel	12 événements majeurs
Ateliers de l'industrie	Semestriel	6 ateliers
Réunions d'examen des clients	Mensuel	48 Interactions du client

Evogene Ltd. (EVGN) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les marchés de la biotechnologie agricole

En 2024, Evogene maintient une équipe de vente directe spécialisée axée sur les marchés de la biotechnologie agricole. L'équipe comprend 12 professionnels des ventes dévoués avec une expertise en biotechnologie et en sciences des cultures.

Métriques de l'équipe de vente	2024 données
Représentants des ventes totales	12
Couverture géographique	Amérique du Nord, Europe, Amérique du Sud
Potentiel de vente annuel moyen par représentant	1,2 million de dollars

Conférences scientifiques et expositions de l'industrie

Evogène participe activement à des conférences clés de biotechnologie agricole pour présenter la technologie et engager des partenaires potentiels.

• Assisté à 7 conférences internationales majeures en 2024
• Présenté 15 présentations techniques
• Engagé avec plus de 120 partenaires potentiels de l'industrie

Plateformes numériques et technologies en ligne présentant

Canal numérique	2024 Métriques d'engagement
Site Web de l'entreprise	45 000 visiteurs uniques
Page de société LinkedIn	22 500 abonnés
Webinaires techniques	8 hébergés, 1 200 participants au total

Négociations sur les licences technologiques

La chaîne de licence d'Evogene implique des négociations directes avec les sociétés agricoles et biotechnologiques.

• Discussions sur les licences actives avec 6 grandes sociétés agricoles
• Négociations en cours pour 3 plateformes technologiques distinctes
• Revenus de licence potentiels estimés à 5,4 millions de dollars

Réseaux de publication académique et de l'industrie

Catégorie de publication	2024 mesures
Publications de journal évaluées par des pairs	12 articles scientifiques
Présentations du journal de conférence	18 présentations techniques
Impact de la citation	Citations moyennes par papier: 7,3

Evogene Ltd. (EVGN) - Modèle d'entreprise: segments de clientèle

Sociétés de semences agricoles

Evogène dessert les grandes sociétés de semences agricoles avec des technologies d'amélioration génétique ciblées.

Type de client	Pénétration du marché	Investissement potentiel
Grandes sociétés de semences	12 partenariats mondiaux	Valeur de collaboration moyenne de 3,5 millions de dollars
Sociétés de semences de taille moyenne	8 collaborations actives	1,2 million de dollars d'investissement moyen du projet

Entreprises de production agricole

Evogène fournit des solutions génétiques pour les producteurs de cultures commerciales.

• Concentrez-vous sur les segments de production de maïs, de soja et de blé
• Cible des fermes commerciales avec une zone de culture> 500 hectares
• Amélioration potentielle du rendement: 7-12% par intervention génétique

Entreprises technologiques agricoles mondiales

Evogene collabore avec des sociétés de technologie agricole avancées.

Catégorie de partenaires technologiques	Nombre de partenariats	Valeur de collaboration annuelle
Entreprises de biotechnologie	6 partenariats actifs	2,8 millions de dollars
Sociétés d'agriculture de précision	4 projets collaboratifs	1,5 million de dollars

Institutions de recherche

Evogene soutient les programmes de recherche universitaires et gouvernementaux.

• Collaborations avec 9 universités de recherche internationale
• Financement de la subvention de recherche: 750 000 $ par an
• Concentrez-vous sur les technologies de reproduction génomique et moléculaire

Agences gouvernementales de développement agricole

Evogene s'engage dans les programmes gouvernementaux de développement agricole.

Segment du gouvernement	Portée géographique	Investissement du projet
Agences nord-américaines	3 partenariats gouvernementaux actifs	1,6 million de dollars
Services agricoles européens	2 programmes de recherche collaborative	1,2 million de dollars

Evogene Ltd. (EVGN) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2023, Evogene Ltd. a déclaré des dépenses de R&D de 14,2 millions de dollars, ce qui représente une partie importante de leurs coûts opérationnels.

Année	Dépenses de R&D	Pourcentage des dépenses totales
2022	13,7 millions de dollars	42.3%
2023	14,2 millions de dollars	44.1%

Maintenance des infrastructures informatiques

Les coûts annuels de maintenance des infrastructures informatiques pour Evogene étaient d'environ 3,5 millions de dollars en 2023.

• Services de cloud computing: 1,8 million de dollars
• Mises à niveau matériel: 1,2 million de dollars
• Licence de logiciel: 500 000 $

Protection et gestion de la propriété intellectuelle

Evogène a investi 1,6 million de dollars en protection de la propriété intellectuelle en 2023.

Catégorie de coûts IP	Montant
Dépôt de brevet	$750,000
Consultation juridique	$550,000
Entretien IP	$300,000

Salaires spécialisés du personnel scientifique

Les coûts totaux du personnel pour le personnel scientifique spécialisé en 2023 étaient de 9,3 millions de dollars.

• Chercheurs seniors: 4,2 millions de dollars
• Biologistes informatiques: 2,7 millions de dollars
• Soutenir le personnel scientifique: 2,4 millions de dollars

Développement de la technologie et amélioration des plateformes

Les dépenses de développement technologique ont totalisé 5,8 millions de dollars en 2023.

Zone de développement	Investissement
Plate-forme d'IA et d'apprentissage automatique	2,6 millions de dollars
Outils d'analyse génétique	1,9 million de dollars
Systèmes d'intégration de données	1,3 million de dollars

Evogene Ltd. (EVGN) - Modèle d'entreprise: Strots de revenus

Frais de licence de technologie

En 2024, Evogene Ltd. génère des revenus grâce à des frais de licence technologique dans les domaines agricoles et pharmaceutiques.

Zone technologique	Gamme de frais de licence	Contribution annuelle des revenus
Technologies de traits agricoles	250 000 $ - 750 000 $ par licence	1,2 million de dollars
Plates-formes de calcul pharmaceutique	500 000 $ - 1,5 million de dollars par licence	2,3 millions de dollars

Paiements de redevances de la commercialisation des traits

Evogène reçoit des redevances de traits agricoles et biologiques commercialisés.

• Taux de redevance des traits agricoles: 3 à 5% des ventes brutes
• Total des revenus de redevances en 2023: 4,7 millions de dollars
• Revenus de redevances projetés pour 2024: 5,2 millions de dollars

Contrats de collaboration de recherche

Evogene conclut des accords de collaboration de recherche avec des partenaires de l'industrie.

Type de collaboration	Valeur du contrat	Durée
Recherche agricole	1,8 million de dollars	2-3 ans
Recherche pharmaceutique	2,5 millions de dollars	3-4 ans

Paiements basés sur les jalons provenant de partenariats

Evogène reçoit des paiements lors de la réalisation de jalons spécifiques de recherche et de développement.

• Paiement d'étape moyen: 350 000 $ - 750 000 $
• Paiements de jalons totaux en 2023: 2,1 millions de dollars
• Payments d'étape projetés pour 2024: 2,6 millions de dollars

Revenus de transaction de propriété intellectuelle

Evogène génère des revenus grâce à des transactions de propriété intellectuelle stratégiques.

Type de transaction IP	Valeur de transaction	Revenus annuels
Ventes de brevets	1,2 million de dollars	1,2 million de dollars
Licence IP	$850,000	$850,000

Evogene Ltd. (EVGN) - Canvas Business Model: Value Propositions

You're looking at the core promises Evogene Ltd. (EVGN) makes to its customers and partners as of late 2025, focusing on where their proprietary technology delivers tangible, measurable value across their key business units.

ChemPass AI: Accelerating small molecule discovery with 90% precision

The value proposition here is speed and accuracy in finding the right molecule. Evogene Ltd. completed version 1.0 of its generative AI foundation model for small molecule design, which is built upon a massive dataset comprising approximately 38 billion molecular structures. This engine directly addresses the challenge of finding novel molecules that meet multiple criteria simultaneously, a process that used to be sequential and low-probability. The result is a significant leap in efficiency for drug and chemical discovery.

Designing novel, multi-parameter optimized drug candidates for pharma is a major focus, leveraging this AI engine. Small molecule-based drugs currently represent nearly 60% of the global pharmaceutical market, so hitting that target with higher success rates is a huge value driver. The platform's proprietary model achieves 90% precision in novel molecule designs, which is a substantial improvement over the 29% precision seen in traditional GPT AI models for the same task.

Here's a quick look at the core performance metric for the AI engine:

Value Proposition Component	Metric	Value
Novel Molecule Design Precision	Precision Rate	90%
AI Foundation Model Training Data	Molecular Structures	38 billion
Pharma Market Segment Share	Small Molecule Drugs	Nearly 60%

Developing next-generation, sustainable crop protection chemicals (AgPlenus)

AgPlenus uses the ChemPass AI tech-engine to design sustainable crop protection chemicals. While specific product efficacy numbers aren't always public, the financial context shows the strategic shift. For the nine months ending September 30, 2025, revenue from AgPlenus activity was lower compared to the same period in 2024, which had included a one-time payment from Bayer in the first quarter of 2024. The company's focus is clearly on leveraging the AI to create better, more sustainable products for this multi-billion dollar market.

Providing high-yield, high-grade castor seed varieties for the biofuel industry (Casterra)

Casterra delivers superior castor seed varieties tailored for industrial-scale biofuel and biopolymer feedstock supply. The value is in the genetics, which are developed using Evogene Ltd.'s GeneRator AI tech-engine. You can see the commercial traction in the financials; seed sales from Casterra were the primary driver of Evogene Ltd.'s total revenue increase to approximately $3.2 million in the first half of 2025, up from approximately $2.3 million in the first half of 2024. The company has also executed on supply chain scaling, with an initial delivery of 250 tons of seed in Brazil as part of its expansion plans.

The genetics themselves offer clear advantages over non-optimized varieties:

• Exceptional germination rate of ~90%, exceeding industry benchmarks.
• High oil content, with some varieties reaching 48% to 50% oil content.
• Grain yield potential around 2.5 Ton/Ha for key varieties.
• Seed cycle time as short as 120 to 140 days from sowing to harvest for certain types.

The overall financial health supporting these value propositions as of the end of Q3 2025 was a consolidated cash position of approximately $16.0 million, with a streamlined operating expense base of approximately $2.9 million in Q3 2025, showing a commitment to maintaining runway while advancing core assets.

Evogene Ltd. (EVGN) - Canvas Business Model: Customer Relationships

You're looking at how Evogene Ltd. manages its relationships with the entities that buy its technology or products as of late 2025. The strategy has clearly shifted, emphasizing direct engagement and leveraging the core ChemPass AI engine, while Casterra continues to drive product sales.

Strategic, long-term co-development partnerships with revenue sharing.

Evogene Ltd. structures its most strategic relationships, particularly in the pharmaceutical vertical driven by ChemPass AI, around co-development models. The expected upside from these alliances is designed to be multi-faceted, capturing value throughout the product lifecycle, not just at the initial licensing stage. This approach is central to the company's 'Real-World Innovation' focus.

The structure of these potential long-term deals is laid out to capture value through several mechanisms:

Revenue Component	Description/Context (Late 2025)
R&D Fees	Payments received to fund ongoing development work within the partnership.
Milestone Payments	Payments triggered upon the achievement of specific development or regulatory goals.
Revenue-Sharing Mechanism	A percentage of the final end-product sales, indicating a true long-term stake.

A significant foundational collaboration supporting this strategy is the one with Google Cloud, which helped develop the ChemPass-AI foundation model. This model was trained on an unparalleled dataset of approximately 38 billion molecules, enhancing the platform's ability to discover clinically relevant compounds.

For the agricultural side, AgPlenus Ltd. will continue its strategic engagements with existing major partners, namely Bayer and Corteva, with expectations for new collaborations to emerge in the future.

Direct engagement with biotech and pharma R&D teams.

To accelerate the penetration of the ChemPass AI technology into the pharma vertical, Evogene Ltd. is actively building out its direct relationship management capabilities. This is a shift toward more hands-on, collaborative development rather than purely licensing out the engine.

Key elements defining this direct engagement include:

• Building a dedicated business development team in pharma.
• Planning to expand academic and industry collaborations globally.
• Announcing a collaboration in August 2025 with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease.

This direct approach helps ensure that the AI-designed molecules meet the maximum number of defined drug key parameters, aiming to improve the probability of successfully progressing through clinical trial stages.

Dedicated sales and marketing for Casterra's industrial seed customers.

Casterra Ag, Evogene Ltd.'s subsidiary focused on castor seed varieties for the biofuel and biopolymer industries, remains a key driver of current revenue, even as the parent company focuses on ChemPass AI. Sales and marketing efforts are dedicated to fulfilling these industrial seed orders.

Here are the concrete numbers related to Casterra's customer base and sales performance through the first three quarters of 2025:

Metric	Value (As of Late 2025 Data)
Revenue Driver (H1 2025)	Increased seed sales drove revenue growth in the first half of 2025.
Q3 2025 Sales Performance	Seed sales were reduced in the third quarter of 2025 compared to Q3 2024.
Outstanding Customer Receivables (Q1 2025)	Approximately $2.0 million due from Casterra's outstanding customers as of March 31, 2025.
Expected Collection of Receivables	The majority of the $2.0 million was expected to be received in the second quarter of 2025.
Prior Order Backlog (as of mid-2024)	Anticipated remaining revenue from 2023/2024 orders was approximately $8.4 million, expected to be recognized in the second half of 2024.

For the nine months ending September 30, 2025, the increase in Casterra's seed sales partially offset lower revenue from AgPlenus' activities. The company's total Sales and Marketing expenses for the nine months of 2025 were approximately $1.2 million.

Evogene Ltd. (EVGN) - Canvas Business Model: Channels

You're looking at how Evogene Ltd. gets its technology and products to market as of late 2025, which is a mix of direct sales, partnerships, and validation through science. The company has been streamlining, which definitely changes the channel emphasis compared to previous years.

Direct licensing and collaboration agreements with global corporations

Evogene Ltd. continues to use its tech-engines, like ChemPass-AI, to enter into agreements with larger entities in the pharma and agriculture sectors. This channel is designed for upfront payments, R&D fees, and future royalties, though recent financial reporting shows a shift away from large, one-time license fees.

For the nine months ending September 30, 2025, total revenues were approximately $3.5 million. This compares to approximately $4.0 million in the same period in 2024. The year-over-year revenue decrease was primarily driven by lower revenue from AgPlenus' activity, which included a one-time payment from Bayer in the first quarter of 2024, and revenues recognized from the Corteva collaboration which was completed during 2024.

The strategic focus now includes signing additional collaboration agreements with biotech and later pharma partners for small molecule drug development, and expanding collaborations with existing and new leading ag-chem companies. A major channel shift involved the sale of most of Lavie Bio's activity and the MicroBoost AI for Ag tech-engine to ICL in July 2025, which generated a total of $18.71 million.

Here's a look at how revenue sources have changed across the reporting periods:

Revenue Component/Period	Q1 2024 Revenue (Approx.)	9 Months Ended Sept 30, 2025 Revenue (Approx.)
Total Revenues	$4.2 million	$3.5 million
License Fee Payments (Q1 only)	$3.5 million (from Lavie Bio/Corteva & AgPlenus/Bayer)	Not specified as a separate line item, lower overall license revenue reflected in total
Revenue from Casterra Seed Sales	Not the primary driver in Q1 2024	Partially offset the decrease in license revenue

Subsidiary-led commercial sales channels for Casterra's seeds

Casterra Ag Ltd. uses a direct sales channel, focusing on integrated solutions for large-scale castor bean farming using the GeneRator AI tech-engine. This channel saw significant growth early in 2025, though it softened later in the year.

In the first quarter of 2025, Casterra delivered approximately 250 tons of castor seeds to a partner in Africa. This surpassed the approximately 215 tons delivered in the entire year of 2024. The company was also strengthening its sales team in Brazil and executing a new marketing and sales strategy. Casterra's increased seed sales were the main driver of Evogene Ltd.'s revenue in Q1 2025.

However, the channel faced headwinds by the third quarter of 2025. Revenues for Q3 2025 were only approximately $0.3 million, a sharp drop from approximately $1.7 million in Q3 2024, which was mainly attributed to reduced seed sales generated by Casterra during the third quarter of 2025. As of March 31, 2025, Casterra had approximately $2.0 million in outstanding customer receivables, with the majority expected in the second quarter of 2025.

Scientific publications and conference presentations for technology validation

Technology validation channels rely on peer review and industry visibility to support the value proposition of Evogene Ltd.'s AI platforms, which underpins future licensing deals.

The company is actively using conference presentations to communicate progress. Evogene Ltd. was scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference in New York.

Internal technology milestones serve as validation points for potential partners:

• Biomica is expected to complete its clinical trial for BMC128 by early 2026.
• Evogene Ltd. is focused on maintaining its technological edge with the ChemPass AI platform.

Finance: review Q4 2025 cash burn projections by next Tuesday.

Evogene Ltd. (EVGN) - Canvas Business Model: Customer Segments

You're looking at the core groups Evogene Ltd. targets with its AI-driven discovery platforms, especially after the strategic streamlining completed by late 2025.

Global pharmaceutical and biotech companies

This segment is central to the focus on the ChemPass AI tech-engine for small molecule drug discovery. Evogene Ltd. collaborates with these entities to co-develop innovative drugs, aiming to reduce development time and cost. A concrete example of this focus includes a collaboration announced in August 2025 with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease. The platform is designed to navigate uncharted chemical space to deliver finely optimized molecules. The company emphasizes capturing substantial value across multi-billion-dollar markets in human health.

Major agrochemical and crop protection corporations

Evogene Ltd. serves this market through its subsidiary AgPlenus Ltd., which develops next-generation ag chemicals powered by ChemPass AI. This segment has historically involved significant partnerships. For instance, revenue recognized in 2024 included a one-time payment of $1.0 million from AgPlenus's collaboration with Bayer. The global agriculture market, covering herbicides, insecticides, and fungicides, was valued at $79 billion in 2024. Revenue comparisons for 2025 reflect the absence of such large upfront payments from this segment compared to the prior year. The company is optimizing its agricultural offering around ChemPass AI, including a 40% workforce reduction at AgPlenus as part of integration efforts.

Industrial and biofuel producers requiring castor oil feedstock

The customer base here is served by Casterra Ag Ltd., which focuses on developing and marketing superior castor seed varieties. This segment contributes directly to Evogene Ltd.'s revenue through seed sales. For the nine months ending September 30, 2025, an increase in seed sales generated by Casterra partially offset revenue decreases from other areas. Specifically, Casterra's increased seed sales drove revenue in the first quarter of 2025, where total revenues were $2.4 million. Seed sales also contributed to the first half of 2025 total revenues of approximately $3.2 million.

Academic and research institutions for co-development

Evogene Ltd. engages with academic partners to advance its discovery engines. This segment is critical for early-stage validation and novel application development. The collaboration with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease is a direct engagement with a research institution. The company uses its tech-engines to develop products through strategic partnerships and collaborations. The overall strategy involves leveraging its AI platform to increase the probability of success in product development for these partners.

The revenue contribution and partnership activity related to these segments can be summarized as follows:

Customer/Partner Type Driver	Relevant Financial Period	Reported Amount/Value
Revenue from Casterra Seed Sales	Q1 2025	Primary driver of $2.4 million revenue
Revenue from AgPlenus/Bayer License Fee (One-time)	Q1 2024 (Comparative)	$1.0 million recognized
Revenue from Lavie Bio/Corteva License Fee	Q1 2024 (Comparative)	$2.5 million recognized
Total Nine Months 2025 Revenue (All Segments)	9M 2025 (Ending Sep 30)	Approximately $3.5 million
Total Nine Months 2025 Revenue from Discontinued Ops (Lavie Bio/MicroBoost AI)	Q3 2025 (Income, net)	Approximately $7.9 million

Evogene Ltd.'s focus on its core engine, ChemPass AI, means the structure of its customer engagement is shifting toward licensing and collaboration models that provide R&D fees, milestone payments, and revenue sharing on end products. The company's cash position as of September 30, 2025, stood at approximately $16.0 million, which supports continued focused engagement with these key customer groups.

• Focus on small molecule drug discovery for pharma.
• Advancing ag-biologicals and ag-chemicals via partnerships.
• Generating value from superior castor seed varieties.
• Co-developing therapeutics with academic experts.

Evogene Ltd. (EVGN) - Canvas Business Model: Cost Structure

You're looking at the cost base for Evogene Ltd. (EVGN) as they pivot hard into being a focused, AI-driven small molecule design company. The cost structure reflects significant streamlining efforts completed by the end of Q2 2025, which you see the full effect of in the Q3 numbers.

The company has been aggressive in cutting costs outside its core focus areas, which directly impacts the reported figures. For instance, the total operating expenses, net, were slashed to approximately $2.9 million in Q3 2025, a major drop from approximately $6.6 million in the same period of 2024. This new expense level is expected to be maintained going forward.

High R&D expenses for AI platform development and validation remain a core cost, even with overall reductions. The company is investing in its ChemPass AI tech-engine, which is central to its strategy.

Here's a breakdown of the key expense components for the first nine months of 2025 compared to the prior year:

Expense Category	9 Months Ended Sept 30, 2025 (Approx.)	9 Months Ended Sept 30, 2024 (Approx.)
Research and Development Expenses, net of grants	$6.2 million	$9.8 million
Sales and Marketing Expenses	$1.2 million	$1.6 million

The R&D spend for the third quarter of 2025 specifically was approximately $1.4 million, down from approximately $3.3 million in Q3 2024. This reduction was primarily due to decreased expenses in Biomica and the cessation of Canonic's operations.

Personnel costs for computational scientists and biologists are a significant component of the operating expenses, even after streamlining. Evogene initiated and executed a cost reduction plan, which included a workforce reduction of approximately 30%, with the full effect reflected starting in Q3 2025. Decreases in Sales and Marketing Expenses were mainly attributed to reductions in personnel costs across Evogene, AgPlenus, and Biomica.

Clinical trial and regulatory costs for Biomica's drug candidates are managed under the reduced R&D umbrella. Biomica is focused on completing its clinical trial for BMC128 by early 2026. The financial results for the nine months of 2025 showed a decrease in R&D expenses, which was partly due to reduced R&D expenses in Biomica.

You can see how the overall operating loss improved due to these cost controls:

• Operating Loss for the nine months of 2025 was approximately $8.8 million, a significant decrease from approximately $15.3 million in the same period of 2024.
• Operating Loss for Q3 2025 was approximately $2.7 million, down from approximately $5.9 million in Q3 2024.
• General and administrative expenses for Q3 2025 decreased to approximately $1.1 million compared to approximately $2.8 million in the same period last year.

Finance: draft 13-week cash view by Friday.

Evogene Ltd. (EVGN) - Canvas Business Model: Revenue Streams

You're looking at Evogene Ltd.'s (EVGN) revenue streams as of late 2025, which are heavily influenced by recent strategic divestitures and the core business's evolving performance. The company's reported revenue for the first nine months ending September 30, 2025, totaled approximately $3.5 million, marking a decrease from approximately $4.0 million in the corresponding nine-month period last year.

The primary components shaping Evogene Ltd.'s reported income streams reflect a transition period, with significant non-recurring income from asset sales dominating the Q3 results. The ongoing revenue from the core business is now more concentrated, especially in the agricultural technology segment.

Here is a breakdown of the key revenue and income elements impacting Evogene Ltd. as of the nine months ended September 30, 2025:

• Collaboration fees and milestone payments from licensing agreements.
• Revenue sharing/royalties on commercialized end-products.
• Seed sales revenue from Casterra, which partially offset a revenue decrease in the 9M 2025 period.
• Income from discontinued operations (Lavie Bio sale) of approximately $7.9 million in Q3 2025.

The income derived from discontinued operations is a major financial event for the period. This line item includes the financial impact of the sale of the majority of Lavie Bio Ltd.'s activities to ICL Group Ltd., which was finalized in July 2025, alongside the sale of the MicroBoost AI for Ag tech-engine to ICL. For the third quarter of 2025 alone, this generated income, net, of approximately $7.9 million, a significant swing from a loss of approximately $1.5 million in Q3 2024.

For the nine months ending September 30, 2025, the total income from discontinued operations, net, was approximately $5.7 million, compared to a loss of approximately $2.2 million for the same nine months in 2024. The overall revenue decrease of approximately $0.5 million for the nine months of 2025 was attributed to lower revenue from AgPlenus' activity, which had included a one-time payment from Bayer during the first quarter of 2024. This decline was partially counteracted by an increase in seed sales generated by Casterra.

To give you a clearer picture of the financial flow around the reporting date, here's a look at the key income/expense items for the nine months ending September 30, 2025, versus the prior year:

Financial Metric	Nine Months Ended Sept 30, 2025	Nine Months Ended Sept 30, 2024
Total Revenues	Approximately $3.5 million	Approximately $4.0 million
Income (Loss) from Discontinued Operations, Net	Approximately $5.7 million (Income)	Approximately ($2.2 million) (Loss)
Financial Income (Expense), Net (Warrants)	Approximately $674,000 (Income)	Approximately ($881,000) (Expense)

While specific figures for ongoing collaboration fees, milestones, or royalties aren't detailed separately in the top-line revenue figures, the overall $3.5 million in 9M 2025 revenue represents the current operational income base before considering the large, non-recurring income from the asset sales. Also, you should note the financial income related to warrants; for the nine months of 2025, this was approximately $674,000 in income, a positive shift from financing expenses net of approximately $881,000 in the same period of 2024. That's a swing of over $1.5 million just on that financing line.